Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10876431 | 0.97 | CYP1A2 (0.36) | CYP1A2CHRM2CYP2D6CHRM1KCNH2 | |
| SCHEMBL10876420 | 0.97 | CYP1A2 (0.36) | CYP1A2CHRM2CYP2D6CHRM1KCNH2 | |
| SCHEMBL12820607 | 0.95 | — | — | |
| SCHEMBL458137 | 0.89 | — | — | |
| SCHEMBL24943892 | 0.80 | KEAP1 (0.33) | ALDH1A1 | |
| SCHEMBL28578100 | 0.78 | CYP1A2 (0.38) | CYP1A2CHRM2CYP2D6CHRM1KCNH2 | |
| SCHEMBL11981967 | 0.78 | CYP1A2 (0.38) | CYP1A2CHRM2CYP2D6CHRM1KCNH2 | |
| SCHEMBL22421512 | 0.78 | — | — | |
| SCHEMBL13893229 | 0.78 | HSD11B1 (0.33) | — | |
| SCHEMBL17818897 | 0.77 | MEN1 (0.33) | CYP2D6SMN1; SMN2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2192134-B1 | PHOTOSENSITIVE COMPOSITION, PATTERN-FORMING METHOD USING THE PHOTOSENSITIVE COMPOSITION, AND COMPOUND USED IN THE PHOTOSENSITIVE COMPOSITION | FUJIFILM CORP (JP) | 2014-02-26 | — | — | EP | disclosed |
| EP-1975716-A2 | Positive resist composition and pattern forming method | Fujifilm Corporation (JP) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX3, P2RX7, P2RX2 | CYP1A2 1617/4885CHRM2 201/4885CYP2D6 1779/4885 |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | CYP1A2 3864/4885CHRM2 2750/4885CYP2D6 4088/4885 |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | CYP1A2 3864/4885CHRM2 2750/4885CYP2D6 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.